Abstract:Intrahepatic cholangiocarcinoma (ICC) is one of the most common malignant liver tumors after hepatocellular carcinoma, the incidence rate of which in our country is rather high. At present, surgical resection is still main treatment for ICC. However, due to the lack of specific symptoms at early stage, ICC patients are often diagnosed at late stage and loss of the opportunity of surgical treatments. Conversion therapy is a novel concept proposed recently. It demonstrated that malignant tumors that cannot be resected initially can be downsized by various treatments, so that patients obtained the chance of surgical treatments and get prolonged survival time. With the development of novel anti-tumor drugs, conversion therapy of ICC also is in the first flush of dawn. This review summarizes the current situation of ICC conversion therapy and our practical experience.